Physician profile
Dannis E Hood
NPI 1083603708
$14,123.49
in general payments reported to CMS, 2019-2025
40 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $628 · 2021: $1,155 · 2022: $1,659 · 2023: $3,897 · 2024: $2,688 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,068 · Travel and Lodging: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,067.79 |
| Travel and Lodging | $2,249.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,198.35 | 2019-2025 | Watchman Flx, General - Brady, Watchman Access System |
| Medtronic, INC. | $2,114.94 | 2022-2025 | Micra, Linq II, Selectsecure |
| Novartis Pharmaceuticals Corporation | $1,997.12 | 2019-2025 | |
| Abbott Laboratories | $1,594.57 | 2020-2025 | Cardiomems, Jot Dx, Aveir |
| Cvrx, INC. | $869.42 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $603.12 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $504.81 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Merck Sharp & Dohme LLC | $492.06 | 2021-2025 | Verquvo |
| Abiomed | $387.35 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $333.31 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $304.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $253.81 | 2019-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.39 | 2021-2025 | Jardiance |
| Cardiovascular Systems INC. | $223.19 | 2019-2022 | |
| Amarin Pharma, INC. | $222.26 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dannis Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.